We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Statins May Help Block Transmission of Lyme Disease

By LabMedica International staff writers
Posted on 31 May 2016
A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease.

Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. More...
This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.

Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.

In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.

Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.

"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."

Related Links:
University of Texas at San Antonio


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.